Peptic ulcer disease (PUD) remains a prevalent condition worldwide, necessitating an updated understanding of its pathophysiology, diagnosis, and treatment. This article presents a comprehensive approach to PUD, highlighting recent advancements in management and treatment strategies.
While Helicobacter pylori and nonsteroidal anti-inflammatory drugs (NSAIDs) remain the primary etiological agents, recent studies underscore the role of genetic predisposition, stress, and other lifestyle factors. An individualized approach to PUD, considering these multifactorial causes, optimizes patient outcomes.
Endoscopy continues to be the gold standard for PUD diagnosis. However, non-invasive tests like urea breath tests, stool antigen tests, and serologic tests for H. pylori have gained prominence due to their convenience and accuracy.
First-line treatment for PUD involves eradicating H. pylori with triple or quadruple therapy, alongside proton pump inhibitors (PPIs). For NSAID-induced ulcers, discontinuation of NSAIDs and PPI therapy are recommended. Recent advancements include the use of vonoprazan, a potassium-competitive acid blocker, showing superior efficacy to PPIs in certain populations. Moreover, the role of probiotics in enhancing H. pylori eradication and reducing side effects of antibiotics is gaining recognition.
Healthcare professionals must educate patients about lifestyle modifications, such as avoiding NSAIDs, limiting alcohol, and cessation of smoking. Emphasizing the importance of adherence to medication regimens is crucial to prevent recurrence.
Managing PUD effectively requires an updated, comprehensive approach considering the latest advancements in pathophysiology, diagnosis, and treatment. An individualized treatment plan, coupled with patient education, can significantly improve patient outcomes and prevent recurrence. As healthcare professionals, our role in staying abreast with these updates and implementing them in practice is vital.
1.
High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy
2.
Papillary thyroid cancer: New markers offer hope for tailored treatment
3.
What Comes After Cancer?
4.
FDA Expands Durvalumab Label to Operable Lung Cancer
5.
In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.
1.
Finding Support: Connecting with the Vitiligo Community
2.
Essential Updates in Hematology in Daily Practice
3.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
4.
Living Better With Advanced Cancer Through Supportive Care
5.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
2.
Updates on Standard V/S High Risk Myeloma Treatment
3.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation